Abstract 1496
Background
The pharmacokinetic (PK)/pharmacodynamic (PD), safety and immunogenicity profiles of Sandoz biosimilar pegfilgrastim (Ziextenzo®) and EU reference pegfilgrastim were shown to be similar in a pivotal phase I study. Similarity of efficacy and safety to the reference was demonstrated in two phase III studies in breast cancer patients receiving myelosuppressive chemotherapy. This 3-way study aimed to confirm similarity of PK/PD, safety and immunogenicity to US reference pegfilgrastim, and to bridge between the EU and US reference medicines.
Methods
This randomized, double-blind, 3-treatment, 6-sequence crossover phase I study included healthy volunteers (HVs) administered pegfilgrastim (biosimilar, EU reference, or US reference) once per treatment period. Primary objectives were to demonstrate PK similarity in AUC0-inf, AUC0-last and Cmax, and PD similarity in ANC AUEC0-last and ANC Emax. The study was powered (90%) to achieve confidence intervals within biosimilarity margins 0.8–1.25 in pairwise comparisons (biosimilar vs US reference, biosimilar vs EU reference, and US reference vs EU reference). Secondary objectives were safety, immunogenicity and additional PK/PD parameters.
Results
The study included 577 male and female HVs. PK and PD similarity were demonstrated for primary PK and PD parameters between Sandoz biosimilar, US reference, and EU reference (Table). The safety profile of Sandoz biosimilar pegfilgrastim was similar across groups. Incidence of antidrug antibodies was similar across groups (biosimilar: 31/512 [6.1%]; US reference: 36/511 [7.0%]; EU reference: 39/501 [7.8%]). Secondary PK/PD parameters were also similar.Table:
1815P Summary of PK and PD similarity
Ratio | CI 90% | ||
---|---|---|---|
Biosimilar / US-reference | AUC0-last | 1.0635 | 1.0087, 1.1213 |
AUEC0-last | 0.9997 | 0.9912, 1.0082 | |
Biosimilar / EU-reference | AUC0-last | 1.0469 | 0.9929, 1.1038 |
AUEC0-last | 1.0012 | 0.9927, 1.0098 | |
US-reference / EU-reference | AUC0-last | 0.9844 | 0.9336, 1.0380 |
AUEC0-last | 1.0015 | 0.9930, 1.0101 |
Conclusions
Sandoz biosimilar demonstrated similar PK/PD, safety, tolerability and immunogenicity to US reference and EU reference pegfilgrastim in this large 3-way crossover phase I study.
Clinical trial identification
EudraCT: 2016-003549-27.
Editorial acknowledgement
Caroline McGown of Spirit Medical Communications Ltd, supported by Hexal AG.
Legal entity responsible for the study
Hexal AG.
Funding
Hexal AG.
Disclosure
M. Velinova: Full / Part-time employment: PRA; Honoraria (self), compensation as lead Principal Investigator in the study: Sandoz Biopharmaceuticals. A. Bellon: Full / Part-time employment: Hexal AG. R. Nakov: Full / Part-time employment: Hexal AG. S. Schussler: Full / Part-time employment: Sandoz Inc. S. Schier-Mumzhiu: Full / Part-time employment: Hexal AG. C. Schelcher: Full / Part-time employment: Hexal AG. S.D. Koch: Full / Part-time employment: Hexal AG. A. Skerjanec: Full / Part-time employment: Novartis. J. Wang: Full / Part-time employment: Sandoz Inc. A. Krendyukov: Full / Part-time employment: Hexal AG. G.P. Otto: Full / Part-time employment: Hexal AG.
Resources from the same session
4242 - HIV, HBV and HCV screening practices in oncology: a cross-sectional interregional survey
Presenter: Isabelle Poizot-Martin
Session: Poster Display session 1
Resources:
Abstract
1267 - Genetic landscape of KEAP1 and NFE2L2 mutated cancers from the AACR GENIE database
Presenter: Mark Zaki
Session: Poster Display session 1
Resources:
Abstract
878 - β-arrestin1 is involved in the Ras-induced malignant transformation
Presenter: Takashi Shibano
Session: Poster Display session 1
Resources:
Abstract
4143 - Incidence of second cancer among PLWHIV: retrospective observational study of a series of 601 patients in the French CANCERVIH network
Presenter: Jean-Philippe Spano
Session: Poster Display session 1
Resources:
Abstract
5145 - A challenging task – Identifying carcinoma of unknown primary (CUP) patients according to ESMO guidelines: the CUPISCO trial experience
Presenter: Chantal Pauli
Session: Poster Display session 1
Resources:
Abstract
1737 - Incidence and Outcome of chronic lymphocytic leukemia with Deletion 17p: An Indian experience; challenges and opportunities
Presenter: Ajay Gogia
Session: Poster Display session 1
Resources:
Abstract
2596 - Driving solo? Investigation into collaborating mutations in SDH-deficient neoplasia
Presenter: Jonathan Killian
Session: Poster Display session 1
Resources:
Abstract
1499 - The potential of a novel antiangiogenic VEGFR1-D2 binding peptide in oncology therapeutics
Presenter: Afsaneh Sadre Momtaz
Session: Poster Display session 1
Resources:
Abstract
1775 - First-in-human phase I study of TAS-117, an allosteric AKT inhibitor, in patients with advanced solid tumors
Presenter: Mayu Yunokawa
Session: Poster Display session 1
Resources:
Abstract
4584 - First-in-human study of ABBV-621 in patients (pts) with previously treated sold tumors: Dose-optimization cohorts
Presenter: Emiliano Calvo
Session: Poster Display session 1
Resources:
Abstract